Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by O Shaughnessy Asset Management LLC

O Shaughnessy Asset Management LLC grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 53.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 317,302 shares of the biopharmaceutical company’s stock after purchasing an additional 110,056 shares during the period. O Shaughnessy Asset Management LLC’s holdings in Gilead Sciences were worth $29,309,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in GILD. Walled Lake Planning & Wealth Management LLC increased its holdings in shares of Gilead Sciences by 1.4% in the fourth quarter. Walled Lake Planning & Wealth Management LLC now owns 85,435 shares of the biopharmaceutical company’s stock valued at $7,892,000 after buying an additional 1,165 shares in the last quarter. Brandywine Global Investment Management LLC boosted its stake in shares of Gilead Sciences by 330.8% during the 4th quarter. Brandywine Global Investment Management LLC now owns 740,097 shares of the biopharmaceutical company’s stock worth $68,363,000 after acquiring an additional 568,319 shares in the last quarter. CIBC Private Wealth Group LLC grew its holdings in shares of Gilead Sciences by 7.1% in the 4th quarter. CIBC Private Wealth Group LLC now owns 45,205 shares of the biopharmaceutical company’s stock worth $4,030,000 after acquiring an additional 2,983 shares during the last quarter. IPG Investment Advisors LLC acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $217,000. Finally, Summit Securities Group LLC boosted its position in shares of Gilead Sciences by 942.7% in the 4th quarter. Summit Securities Group LLC now owns 21,897 shares of the biopharmaceutical company’s stock valued at $2,023,000 after purchasing an additional 19,797 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 142,180 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $97.22, for a total value of $13,822,739.60. Following the completion of the transaction, the chief financial officer now owns 129,873 shares of the company’s stock, valued at $12,626,253.06. This represents a 52.26 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold a total of 302,785 shares of company stock valued at $30,503,250 in the last ninety days. Company insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on GILD shares. Royal Bank of Canada upped their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research note on Wednesday, February 12th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and raised their price objective for the stock from $80.00 to $120.00 in a research note on Tuesday, February 18th. Oppenheimer boosted their target price on shares of Gilead Sciences from $115.00 to $132.00 and gave the company an “outperform” rating in a research note on Tuesday, March 4th. Finally, BMO Capital Markets raised their target price on Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 12th. Eleven analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $105.12.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $111.79 on Friday. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96. The firm has a fifty day simple moving average of $105.48 and a 200-day simple moving average of $94.90. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The stock has a market capitalization of $139.22 billion, a price-to-earnings ratio of 302.14, a PEG ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Friday, March 14th were paid a dividend of $0.79 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.83%. The ex-dividend date was Friday, March 14th. Gilead Sciences’s dividend payout ratio is presently 854.05%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.